In silico modeling of phosphorylation dependent and independent c-Myc degradation

Backgroundc-Myc plays an important role in cell proliferation, cell growth and in differentiation, making it a key regulator for carcinogenesis and pluripotency. Tight control of c-myc turnover is required by ubiquitin-mediated degradation. This is achieved in the system by two F-box proteins Skp2 and FBXW7.ResultsDynamic modelling technique was used to build two exclusive models for phosphorylation dependent degradation of Myc by FBXW7 (Model 1) and phosphorylation independent degradation by Skp2 (Model 2). Sensitivity analysis performed on these two models revealed that these models were corroborating experimental studies. It was also seen that Model 1 was more robust and perhaps more efficient in degrading c-Myc. These results questioned the existence of the two models in the system and to answer the question a combined model was hypothesised which had a decision making switch. The combined model had both Skp2 and FBXW7 mediated degradation where again the latter played a more important role. This model was able to achieve the lowest levels of ubiquitylated Myc and therefore functioned most efficiently in degradation of Myc.ConclusionIn this report, c-Myc degradation by two F-box proteins was mathematically evaluated based on the importance of c-Myc turnover. The study was performed in a homeostatic system and therefore, prompts the exploration of c-Myc degradation in cancer state and in pluripotent state.

[1]  Z. Qu,et al.  Roles of Protein Ubiquitination and Degradation Kinetics in Biological Oscillations , 2012, PloS one.

[2]  Shinya Kuroda,et al.  Prediction and validation of the distinct dynamics of transient and sustained ERK activation , 2005, Nature Cell Biology.

[3]  Amit Kumar,et al.  Phosphoinositide 3-Kinase Activation in Late G1 Is Required for c-Myc Stabilization and S Phase Entry , 2006, Molecular and Cellular Biology.

[4]  Walter Kolch,et al.  When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling , 2013, Cell Communication and Signaling.

[5]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[6]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[7]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[8]  K. Nakayama,et al.  Degradation of p27 Kip1 at the G0-G1 Transition Mediated by a Skp2-independent Ubiquitination Pathway* , 2001, The Journal of Biological Chemistry.

[9]  M. Gregory,et al.  c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells , 2000, Molecular and Cellular Biology.

[10]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[11]  Guang Yao,et al.  Sensing and Integration of Erk and PI3K Signals by Myc , 2008, PLoS Comput. Biol..

[12]  B. Lutterbach,et al.  Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis , 1994, Molecular and cellular biology.

[13]  Sudipto Saha,et al.  MYCbase: a database of functional sites and biochemical properties of Myc in both normal and cancer cells , 2017, BMC Bioinformatics.

[14]  S. Elledge,et al.  Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase , 2001, Science.

[15]  S. Elledge,et al.  The role of protein stability in the cell cycle and cancer. , 1998, Biochimica et biophysica acta.

[16]  Srijeeta Talukder,et al.  Deciphering Parameter Sensitivity in the BvgAS Signal Transduction , 2016, PloS one.

[17]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[18]  Lan K. Nguyen,et al.  Dynamics of ubiquitin-mediated signalling: insights from mathematical modelling and experimental studies , 2016, Briefings Bioinform..

[19]  Michele Pagano,et al.  Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. , 2003, Advances in cancer research.

[20]  S. Murray,et al.  myc maintains embryonic stem cell pluripotency and self-renewal. , 2010, Differentiation; research in biological diversity.

[21]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[22]  Aaron Ciechanover,et al.  Proteolysis: from the lysosome to ubiquitin and the proteasome , 2005, Nature Reviews Molecular Cell Biology.

[23]  C. Dang,et al.  Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. , 1997, Journal of biomedical science.

[24]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[25]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[26]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Ciechanover,et al.  Degradation of MYCN oncoprotein by the ubiquitin system. , 1991, Progress in clinical and biological research.

[28]  G. Rangarajan,et al.  Disorder, oscillatory dynamics and state switching: the role of c-Myc. , 2015, Journal of theoretical biology.

[29]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[30]  S. Reed,et al.  hCDC4 gene mutations in endometrial cancer. , 2002, Cancer research.

[31]  K. Nakayama,et al.  The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. , 2003, Molecular cell.

[32]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[33]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[34]  John J Tyson,et al.  A model for restriction point control of the mammalian cell cycle. , 2004, Journal of theoretical biology.